Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis.

Abstract

BACKGROUND & AIMS:

Acute-on-chronic liver failure (ACLF) is a newly described syndrome, which develops in patients with acute decompensation of cirrhosis, and is characterized by intense systemic inflammation, multiple organ failures and high short-term mortality. The profile of circulating lipid mediators, which are endogenous signaling molecules that play a major role in inflammation and immunity, is poorly characterized in ACLF.

METHODS:

In the current study, we assessed the profile of lipid mediators by liquid chromatography coupled to tandem mass spectrometry in plasma from patients with acute decompensation of cirrhosis, with (n = 119) and without (n = 127) ACLF, and from healthy controls (n = 18). Measurements were prospectively repeated in 191 patients with acute decompensation of cirrhosis during a 28-day follow-up period.

RESULTS:

Fifty-nine lipid mediators (out of 100) were detected in plasma from cirrhotic patients, of which 16 were significantly associated with disease status. Among these, 11 lipid mediators distinguished patients at any stage from healthy controls, whereas 2 lipid mediators (LTE4 and 12-HHT, both derived from arachidonic acid) shaped a minimal plasma fingerprint that discriminated patients with ACLF from those without. Levels of LTE4 distinguished ACLF grade 3 from ACLF grades 1 and 2, followed the clinical course of the disease (increased with worsening and decreased with improvement) and positively correlated with markers of inflammation and non-apoptotic cell death. Moreover, LTE4 together with LXA5 (derived from eicosapentaenoic acid) and EKODE (derived from linoleic acid) were associated with short-term mortality. LXA5 and EKODE formed a signature associated with coagulation and liver failures.

CONCLUSION:

Taken together, these findings uncover specific lipid mediator profiles associated with disease severity and prognosis in patients with acute decompensation of cirrhosis.

LAY SUMMARY:

Acute-on-chronic liver failure (ACLF) is characterized by intense systemic inflammation, multiple organ failures and high short-term mortality. In the current study, we assessed the plasma lipid profile of 100 bioactive lipid mediators in healthy controls, patients with decompensated cirrhosis, and those who had developed ACLF. We identified lipid mediator signatures associated with inflammation and non-apoptotic cell death that discriminate disease severity and evolution, short-term mortality and organ failures.

• Authors: Cristina López-Vicario, Antonio Checa, Arantxa Urdangarin, Ferran Aguilar, José Alcaraz-Quiles, Paolo Caraceni, Alex Amorós, Marco Pavesi, David Gómez-Cabrero, Jonel Trebicka, Karl Oettl, Richard Moreau, Núria Planell, Vicente Arroyo, Craig E Wheelock, Joan Clària
• Journal: Journal of hepatology (J Hepatol) Vol. 73 Issue 4 Pg. 817-828 (10 2020) ISSN: 1600-0641 [Electronic] Netherlands
• PMID: 32294533 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Chemical References

• Biomarkers
• Lipids

Topics

• Acute-On-Chronic Liver Failure (blood)
• Aged
• Biomarkers (blood)
• Female
• Follow-Up Studies
• Humans
• Lipid Metabolism
• Lipidomics (methods)
• Lipids (blood)
• Male
• Middle Aged
• Prognosis
• Severity of Illness Index
• Time Factors